Acorda Therapeutics Inc. reported results from two safety studies conducted for its Parkinson's drug CVT-301.

The company was studying the safety of its drug in patients with asthma, smokers or those experiencing early-morning "off" periods. Off periods are characterized by the re-emergence of Parkinson's symptoms.

The drug showed consistency in safety profile in both investigations as previously reported in phase 2b and phase 3 clinical trials.

In another study, the patients receiving CVT-301 showed no differences in lung function when compared to those in an observational control group.

Acorda Therapeutics plans to file a new drug application for CVT-301 with the U.S. FDA by the end of the second quarter of 2017.